Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success
In Regimen With Keytruda
Executive Summary
The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.